On Friday, Ocular Therapeutix Inc (NASDAQ: OCUL) opened lower -3.45% from the last session, before settling in for the closing price of $7.25. Price fluctuations for OCUL have ranged from $4.06 to $11.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 123.40%. Company’s average yearly earnings per share was noted -16.86% at the time writing. With a float of $132.32 million, this company’s outstanding shares have now reached $156.65 million.
Let’s determine the extent of company efficiency that accounts for 267 employees. In terms of profitability, gross margin is 90.58%, operating margin of -230.12%, and the pretax margin is -284.02%.
Ocular Therapeutix Inc (OCUL) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ocular Therapeutix Inc is 15.83%, while institutional ownership is 73.34%. The most recent insider transaction that took place on Feb 04 ’25, was worth 86,839. In this transaction an insider of this company sold 11,119 shares at a rate of $7.81, taking the stock ownership to the 193,444 shares. Before that another transaction happened on Jan 31 ’25, when Company’s insider sold 6,301 for $7.84, making the entire transaction worth $49,400. This insider now owns 204,563 shares in total.
Ocular Therapeutix Inc (OCUL) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.68% during the next five years compared to 8.38% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Check out the current performance indicators for Ocular Therapeutix Inc (OCUL). In the past quarter, the stock posted a quick ratio of 12.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.07 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Looking closely at Ocular Therapeutix Inc (NASDAQ: OCUL), its last 5-days average volume was 0.84 million, which is a drop from its year-to-date volume of 0.91 million. As of the previous 9 days, the stock’s Stochastic %D was 13.76%. Additionally, its Average True Range was 0.36.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 0.21%, which indicates a significant decrease from 0.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.39% in the past 14 days, which was lower than the 51.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.17, while its 200-day Moving Average is $8.21. However, in the short run, Ocular Therapeutix Inc’s stock first resistance to watch stands at $7.28. Second resistance stands at $7.55. The third major resistance level sits at $7.70. If the price goes on to break the first support level at $6.86, it is likely to go to the next support level at $6.71. Should the price break the second support level, the third support level stands at $6.44.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
There are currently 157,217K shares outstanding in the company with a market cap of 1.10 billion. Presently, the company’s annual sales total 58,440 K according to its annual income of -80,740 K. Last quarter, the company’s sales amounted to 15,430 K and its income totaled -36,490 K.
